A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)

Phase:Open Label
Principal Investigator(s):David Magnuson, PharmD
Objective:This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and following seroconversion, assess the frequency of HIV-1 screening and screening method(s) used for evaluation of seroconverters, and collect information regarding whether the seroconverter experienced signs and symptoms of acute HIV-1 infection prior to or at the time of seroconversion.
Prevention Option(s):PrEP
Study Design:
Official Code: NCT01902472
Trial Sponsors: Gilead
Start Date
End Date
September 4, 2013
June 4, 2018
Age range: 18 Years ↔ any
Population:Cisgender Men, Cisgender Women